Next Article in Journal
Pricing of Orphan Drugs in Oncology and Rare Diseases
Previous Article in Journal
Impact of Non-Medical Switching of Prescription Medications on Health Outcomes: An E-Survey of High-Volume Medicare and Medicaid Physician Providers
 
 
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Use of Complete Clearance for Assessing Treatment Efficacy for 5-Fluorouracil Interventions in Actinic Keratoses: How Baseline Lesion Count Can Impact This Outcome

by
Khaled Ezzedine
1,
Caroline Painchault
2 and
Melanie Brignone
3,*
1
Department of Dermatology, University Hospital Henri Mondor, Créteil, France
2
HEOR department, Keyrus Life Science, Levallois-Perret, France
3
Market access and HEOR department, Pierre Fabre, Boulogne-Billancourt, France
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2020, 8(1), 1829884; https://doi.org/10.1080/20016689.2020.1829884
Submission received: 12 June 2020 / Revised: 18 September 2020 / Accepted: 21 September 2020 / Published: 9 October 2020

Abstract

Background: Many trials in actinic keratoses (AK) use complete clearance rate (100% reduction in number of lesions) as the primary endpoint. We explore limitations (predominantly baseline factors) associated with this outcome. Objective: This analysis assessed the effect of baseline lesion count on complete clearance rate using randomized controlled trials (RCTs) that evaluated 5-fluorouracil (5-FU) formulations, alone or with 10% salicylic acid solution, in patients with AK. Methodology: Correlation between baseline lesion count and complete clearance rate at week 8 was assessed using Pearson’s coefficient. Results: Five RCTs assessing 5-FU (4%, 5%, or 0.5% in 10% salicylic acid solution) in 1,080 patients with AK were included. Mean lesion count at baseline ranged from 8.1 to 21.2 lesions per patient. Complete clearance rate was negatively associated with number of lesions at baseline. Correlation between mean number of lesions at baseline and complete clearance rate was strong (r2 = 0.94) and statistically significant (p < 0.001). Conclusion: This analysis showed that, in a homogenous set of trials, complete clearance rates achieved with 5-FU interventions are inversely related to number of lesions at baseline. These findings highlight the limits of restricting treatment evaluation to complete clearance rate and the relevance of alternative measures.
Keywords: actinic keratosis; systematic literature review; complete clearance rate; clinical trial endpoints; 5-fluorouracil actinic keratosis; systematic literature review; complete clearance rate; clinical trial endpoints; 5-fluorouracil

Share and Cite

MDPI and ACS Style

Ezzedine, K.; Painchault, C.; Brignone, M. Use of Complete Clearance for Assessing Treatment Efficacy for 5-Fluorouracil Interventions in Actinic Keratoses: How Baseline Lesion Count Can Impact This Outcome. J. Mark. Access Health Policy 2020, 8, 1829884. https://doi.org/10.1080/20016689.2020.1829884

AMA Style

Ezzedine K, Painchault C, Brignone M. Use of Complete Clearance for Assessing Treatment Efficacy for 5-Fluorouracil Interventions in Actinic Keratoses: How Baseline Lesion Count Can Impact This Outcome. Journal of Market Access & Health Policy. 2020; 8(1):1829884. https://doi.org/10.1080/20016689.2020.1829884

Chicago/Turabian Style

Ezzedine, Khaled, Caroline Painchault, and Melanie Brignone. 2020. "Use of Complete Clearance for Assessing Treatment Efficacy for 5-Fluorouracil Interventions in Actinic Keratoses: How Baseline Lesion Count Can Impact This Outcome" Journal of Market Access & Health Policy 8, no. 1: 1829884. https://doi.org/10.1080/20016689.2020.1829884

Article Metrics

Back to TopTop